VYRSA Technologies develops sacroiliac joint fusion implants for minimally invasive treatment of chronic SI joint pain. Its V1 system, now called Nevro1, uses integrated lateral transfixation with deployable titanium anchors and became FDA 510(k)-cleared for SI joint fusion in 2022. The company also developed NevroPro, a custom allograft implant designed specifically for the SI joint and offered in multiple sizes for variable anatomy.
FDA 510(k) Clearance
Compliance program
SAIL FusionSAIL Fusion develops sacroiliac-joint fusion technology, applying AO Foundation principles to its proprietary BowTie SI Fusion System. The company’s posterior-inferior approach is designed around minimal tissue disruption, thorough joint preparation and rigid fixation, and its system is offered exclusively to orthopedic and neurological spine surgeons. SAIL Fusion bases its technologies on published scientific evidence and is validating BowTie through biomechanical and clinical research, including a prospective patient study initiated in 2023.SARATOGA SPRINGS, NY
Omnia MedicalFounded by engineers and medical-device professionals, Morgantown, West Virginia-based Omnia Medical develops orthopedic implants for spine and interventional pain care. Its work is especially focused on sacroiliac-joint stabilization, including the PsiFGuard system, which the company describes as FDA-cleared real-time guidance technology for SI-joint detection. Omnia also develops spinal fusion and biologic solutions through surgeon collaboration, with a mission centered on safe, reproducible instrumentation and shorter operative times.MORGANTOWN, WV
ReVivo MedicalReVivo Medical develops spinal-surgery implants, with its CEM-Plate and CEM-Cage currently under investigation in an FDA-sanctioned first-in-human clinical trial. Based in Loudonville, the company was founded by spine surgeons and biomedical researchers to improve patient outcomes while simplifying operating-room workflow and reducing implant components. Its work is backed by 18 issued U.S., European, and Canadian patents, as listed by the company.LOUDONVILLE, NY
SensarsSensars develops implantable neuroprosthetic and neurostimulation systems designed to restore protective sensation in people with diabetic neuropathy and limb loss. Its SENSY platform combines nerve-implanted electrodes with smart wearable insoles, and preliminary human trials have demonstrated sensory restoration, improved gait and reduced pain. The Swiss-founded company’s work has appeared in more than 25 peer-reviewed publications and received FDA Breakthrough Device Designation.